A product specifically indicated in the treatment of rhinosinusitis should act simultaneously on the three clinical characterizations, namely: edema of the rhino-sinus mucosa, slowing or even stopping of ciliary mobility and motility, and accumulation of muco-purulent secretions in the rhino-sinus district and auditory tubes.

Today, there is a product on the market specifically for rhinosinusitis characterized by precisely all three of the above clinical manifestations. This product, which has been developed and patented by Italian researchers, as well as tested in several clinical trials of national and international significance, is marketed under the brand name CiliaCell. The healing efficacy through such a drug is more than 90%.